The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 05, 2021

Filed:

May. 15, 2017
Applicant:

The Trustees of Columbia University IN the City of New York, New York, NY (US);

Inventors:

Changchun Deng, Jericho, NY (US);

Mark Lipstein, New York, NY (US);

Owen O'Connor, Scarsdale, NY (US);

Donald W. Landry, New York, NY (US);

Xiaoming Xu, Fair Lawn, NJ (US);

Shi-Xian Deng, White Plains, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); C07D 471/04 (2006.01); C07D 473/34 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); G01N 33/574 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 471/04 (2013.01); C07D 473/34 (2013.01); G01N 33/57492 (2013.01); G01N 2800/52 (2013.01);
Abstract

The invention relates to new compounds that reduce c-Myc expression and useful for cancer treatment, particularly hematological cancers such as aggressive B- and T-cell lymphomas. The new compounds may be combined with adjunct c-Myc inhibor agents such as a PI3K inhibitor, CK-1 inhibitor, Akt-inhibitor, proteasome inhibitor and/or mTor inhibitor. The c-Myc reducing agent may be provided as a lead-in treatment to reduce or initiate reduction of c-Myc prior to administration of the adjunct cancer therapeutic agent. Treatment with a c-Myc reducing agent modulates the disease state of the c-Myc overexpressing cancer making it less malignant and more susceptible to adjunctive cancer therapies.


Find Patent Forward Citations

Loading…